Since late 2018 we have been waiting for the development of this. Two companies, C4 therapeutics, and Foghorn Therapeutics have been developing treatments. Now Foghorn has received approval for a phase 1/2 IND trial for this BRD9 approval. This treatment is specifically developed for synovial sarcoma. Has any one enrolled in this clinical trial? Any information from doctors?
Here is the announcement: * Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma
Hope this is one breakthrough.